# Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases

## TL;DR

This study finds that bone metastasis prostate cancer patients with additional lymph node metastases have worse initial cancer features but similar long-term outcomes after adjusting for other factors.

## Contribution

Shows that lymph node metastases in bone metastatic prostate cancer do not independently worsen survival when controlling for other factors.

## Key findings

- Patients with M1a + b had significantly higher PSA and higher risk disease features compared to M1b patients.
- Median time to mCRPC was 16 months for M1a + b vs 26 months for M1b patients.
- After adjusting for variables, lymph node metastases did not independently affect time to mCRPC or overall survival.

## Abstract

Most patients with metastatic hormone-sensitive prostate cancer (mHSPC) are burdened by bone metastases. However, the impact of concomitant distant lymph node metastases at diagnosis in these patients is unknown.

We relied on a single-center retrospective mHSPC patient cohort treated between 2014 and 2024 to compare time to metastatic castration-resistant prostate cancer (mCRPC) and overall survival (OS) between M1b vs. M1a + b mHSPC patients. Univariable and multivariable Cox regression models were applied.

Among 432 patients, 64% harbored M1b vs. 36% M1a + b mHSPC. Median PSA was numerically higher (82 vs. 46 ng/ml, p = 0.2) and rates of LATITUDE high-risk (76% vs. 55%) and CHAARTED high-volume disease (70% vs. 50%) were significantly higher in the M1a + b group (both p < 0.001). Regarding time to mCRPC, median time to CRPC was 26 vs. 16 months for M1b vs. M1a + b patients (hazard ratio [HR]: 1.6, p < 0.01). Regarding OS, median OS was not significantly different, with median OS of 53 vs. 47 months for M1b vs. M1a + b patients (p = 0.9). After controlling for patient and tumor characteristics in multivariable Cox regression analyses, concomitant lymph node metastases were not an independent risk for shorter time to CRPC or OS in patients with bone metastases (both p > 0.15).

Patients with concomitant distant lymph node metastases in mHSPC with bone metastases (M1a + b) harbor more unfavorable baseline cancer characteristics relative to M1b without lymph node metastases, translating into significantly shorter time to mCRPC. However, after controlling for patient and tumor characteristics, neither time to mCRPC nor OS seems not be affected by concomitant lymph node metastases.